Thomas Ackerman and Dan Bevevino Join Cryolife, Inc. Board of Directors
December 08 2003 - 8:30AM
PR Newswire (US)
Thomas Ackerman and Dan Bevevino Join Cryolife, Inc. Board of
Directors ATLANTA, Dec. 8 /PRNewswire-FirstCall/ -- CryoLife, Inc.
, announced today that Thomas F. Ackerman and Dan Bevevino have
been elected to the company's Board of Directors, effective
immediately. These two, newly elected board members increase the
number of directors to eight. Thomas F. Ackerman is Senior Vice
President and Chief Financial Officer at Charles River
Laboratories, a provider of critical research tools and integrated
support services that accelerate drug discovery and research. He is
responsible for overseeing the Accounting and Finance departments,
as well as the Information Technology Group and Investor Relations.
Mr. Ackerman joined Charles River Laboratories in 1988 and now has
more than twenty-five years of combined accounting and
international finance experience. He was named Controller, North
America in 1992 and became Vice President and Chief Financial
Officer in 1996. In 1999, he was named Senior Vice President. Dan
Bevevino is Vice President and Chief Financial Officer at
Respironics, a developer, manufacturer and marketer of medical
devices and programs used for the treatment of patients with sleep
and respiratory disorders. Mr. Bevevino joined Respironics in 1988
and has served in a variety of positions with increasing
responsibility in finance and accounting. Additionally, during his
tenure at Respironics, Mr. Bevevino has been responsible for
certain operating, sales and marketing activities. He served as
Controller from 1990-1994, Chief Financial Officer, Controller from
1994-1996 and was appointed Vice President, Chief Financial Officer
in 1996. "Thomas Ackerman and Dan Bevevino will bring valuable
business experience and financial expertise to our Board of
Directors," said Steven G. Anderson, Chairman and Chief Executive
Officer. "We welcome them to our Board and we look forward to the
contributions they will make to CryoLife." CryoLife, Inc. is a
leader in the processing and distribution of implantable living
human tissues for use in cardiovascular and vascular surgeries
throughout the United States and Canada. The Company's BioGlue(R)
Surgical Adhesive is FDA approved as an adjunct to sutures and
staples for use in adult patients in open surgical repair of large
vessels and is CE marked in the European Community and approved in
Canada for use in soft tissue repair and approved in Australia for
use in vascular and pulmonary sealing and repair. The Company also
manufactures the SynerGraft(R) Vascular Graft, which is CE marked
for distribution within the European Community. For additional
information about the company, visit CryoLife's web site,
http://www.cryolife.com/ . Contact: Joseph T. Schepers Vice
President, Corporate Communications (770) 419-3355 DATASOURCE:
CryoLife, Inc. CONTACT: Joseph T. Schepers, Vice President,
Corporate Communications of CryoLife, Inc., +1-770-419-3355 Web
site: http://www.cryolife.com/
Copyright
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jun 2024 to Jul 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jul 2023 to Jul 2024